BL0020 plus toripalimab for recurrent extensive-stage small cell lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This study tests a new drug (BL0020) combined with an immunotherapy drug (toripalimab) for people with extensive-stage small cell lung cancer that has returned after initial treatment. The goal is to see if this combination can help control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have extensive-stage small cell lung cancer.
- Your cancer must have returned or grown after first-line chemotherapy.
- You must be able to care for yourself (ECOG 0 or 1).
- You must not have certain medical conditions like autoimmune diseases or uncontrolled high blood pressure.
- You must not have active hepatitis B or C, or HIV.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an investigational drug called BL0020 for people whose non-small cell lung cancer has changed into small cell lung cancer after treatment with EGFR inhibitors. The goal is to see if BL0020 can help control the cancer.
This trial tests whether adding toripalimab (an immunotherapy) or toripalimab plus another immunotherapy (tifcemalimab) after standard chemoradiation can help prevent small cell lung cancer from coming back. It is for people with limited-stage disease who have finished initial treatment without the cancer growing.
This Phase 2 trial tests how well two study drugs (and a combination of them) work in people with extensive-stage small cell lung cancer. It’s mainly for patients whose cancer has come back or who couldn’t tolerate at least some standard treatments, and it aims to see if treatment can shrink tumors and be tolerable.
This trial tests a combination of an immunotherapy drug (toripalimab) and chemotherapy for people with advanced small cell lung cancer that has progressed after previous treatments. It aims to see if this combination can help control the cancer.
This study is looking at how well the drug toripalimab works in people with extensive-stage small cell lung cancer when it's the first treatment they receive. It's a real-world study, meaning it observes what happens in everyday medical care.
This trial tests whether giving an immunotherapy drug called toripalimab together with chemotherapy after lung cancer surgery can help prevent small cell lung cancer from coming back. It is for people who had surgery to remove lung cancer and were found to have small cell lung cancer in the removed tissue.
Hear when a new Small Cell Carcinoma of Lung trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.